Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

8drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Brigatinib ×

Brigatinib

This drug is selected. Its supporting articles are shown below.

Brigatinib3

Articles mentioning Brigatinib

3 articles · page 1 of 1

Communicating clinical trial information about cancer drug products to patients and healthcare professionals: review of patient-reported outcome messaging

bmjonc · full text · 2026-04-07 · 4 matching annotations

97.3%

Zykadia Cyramza Fruzaqla Fruquintinib Imfinzi durvalumab ramucirumab Brigatinib ceritinib

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

Surgery as local consolidation therapy before progression in oncogene-driven stage IV NSCLC: a patient and advocacy perspective

bmjonc · full text · 2026-03-24 · 3 matching annotations

98.5%

brigatinib osimertinib oligometastatic NSCLC stage IV lung cancer stage IV NSCLC National Institute for Clinical Excellence systemic therapy NICE NSCLC STS

…-rearranged metastatic NSCLC, median PFS reached 66 months with brigatinib, followed by brigatinib plus LCT (radiation and/or surgery), co…

512 Predictive value of baseline and longitudinal MRI radiomics for intracranial progression-free survival in ALK-positive NSCLC patients with brain metastases

jitc · abstract · 2025-11-04 · 1 matching annotations

97.4%

crizotinib brigatinib brain metastases ALK+ NSCLC ALK-positive NSCLC tyrosine kinase inhibitor (TKI) therapy TKI therapy

…tients with brain metastases treated with ALK TKIs (brigatinib, crizotinib) were analyzed. Radiomic features were extracted from baseline …